Kang S, Schmidt J, Chen I, Tiberi S
IJTLD Open. 2024; 1(12):547-555.
PMID: 39679205
PMC: 11636495.
DOI: 10.5588/ijtldopen.24.0413.
Liang S, Liang H, Huang X, Liang X, Chen N, Xiao R
Emerg Microbes Infect. 2024; 13(1):2396887.
PMID: 39178284
PMC: 11378669.
DOI: 10.1080/22221751.2024.2396887.
Xu N, Li L, Wu S
Heliyon. 2024; 10(15):e35311.
PMID: 39166010
PMC: 11334812.
DOI: 10.1016/j.heliyon.2024.e35311.
Yang S, He Z, Zhang N, Lu M
Cureus. 2024; 16(6):e62313.
PMID: 39006676
PMC: 11246067.
DOI: 10.7759/cureus.62313.
Chotirmall S, Chalmers J
Am J Respir Crit Care Med. 2024; 210(1):24-34.
PMID: 38949497
PMC: 11197062.
DOI: 10.1164/rccm.202403-0473PP.
Characteristics and management of periprosthetic joint infections caused by rapidly growing mycobacteria: a retrospective study and a review of the literature.
Damronglerd P, Higgins E, Fida M, Tai D, Tande A, Abdel M
J Bone Jt Infect. 2024; 9(1):99-106.
PMID: 38601002
PMC: 11002937.
DOI: 10.5194/jbji-9-99-2024.
Proposed Etiotypes for Chronic Obstructive Pulmonary Disease: Controversial Issues.
Kim S, Moon J, Min K, Lee H
Tuberc Respir Dis (Seoul). 2024; 87(3):221-233.
PMID: 38317417
PMC: 11222089.
DOI: 10.4046/trd.2023.0194.
A Novel Inhibitor against the Biofilms of Non-Tuberculous Mycobacteria.
Kaur P, Krishnamurthy R, Shandil R, Mohan R, Narayanan S
Pathogens. 2024; 13(1).
PMID: 38251347
PMC: 10819454.
DOI: 10.3390/pathogens13010040.
A Systematic Review of Factors Associated with Mortality among Patients with Complex Lung Disease.
Fujishima N, Komiya K, Yamasue M, Hiramatsu K, Kadota J
Pathogens. 2023; 12(11).
PMID: 38003795
PMC: 10674274.
DOI: 10.3390/pathogens12111331.
Druggable redox pathways against Mycobacterium abscessus in cystic fibrosis patient-derived airway organoids.
Leon-Icaza S, Bagayoko S, Verge R, Iakobachvili N, Ferrand C, Aydogan T
PLoS Pathog. 2023; 19(8):e1011559.
PMID: 37619220
PMC: 10449475.
DOI: 10.1371/journal.ppat.1011559.
Pleural infection caused by in a patient after lung transplantation.
Plank P, Hinze C, Sedlacek L, Welte T, Suhling H, Gottlieb J
J Clin Tuberc Other Mycobact Dis. 2023; 32:100380.
PMID: 37389012
PMC: 10302558.
DOI: 10.1016/j.jctube.2023.100380.
Novel Synergies and Isolate Specificities in the Drug Interaction Landscape of Mycobacterium abscessus.
Van N, Degefu Y, Leus P, Larkins-Ford J, Klickstein J, Maurer F
Antimicrob Agents Chemother. 2023; 67(7):e0009023.
PMID: 37278639
PMC: 10353461.
DOI: 10.1128/aac.00090-23.
Molecular assessment of mycobacterial burden in the treatment of nontuberculous mycobacterial disease.
Ellis H, Moffatt M, Churchward C, Cuthbertson L, Cookson W, Loebinger M
ERJ Open Res. 2023; 9(2).
PMID: 36949959
PMC: 10026000.
DOI: 10.1183/23120541.00435-2022.
Addressing antimicrobial resistance with the IDentif.AI platform: Rapidly optimizing clinically actionable combination therapy regimens against nontuberculous mycobacteria.
Mukherjee D, Wang P, Hooi L, Sandhu V, You K, Blasiak A
Theranostics. 2022; 12(16):6848-6864.
PMID: 36276648
PMC: 9576615.
DOI: 10.7150/thno.73078.
Clofazimine as a comparator for preclinical efficacy evaluations of experimental therapeutics against pulmonary M. abscessus infection in mice.
Sriram D, Wahi R, Maggioncalda E, Panthi C, Lamichhane G
Tuberculosis (Edinb). 2022; 137:102268.
PMID: 36228452
PMC: 10739713.
DOI: 10.1016/j.tube.2022.102268.
Omadacycline Potentiates Clarithromycin Activity Against .
Hanh B, Quang N, Park Y, Heo B, Jeon S, Park J
Front Pharmacol. 2021; 12:790767.
PMID: 34955859
PMC: 8693020.
DOI: 10.3389/fphar.2021.790767.
